Quantcast

Industry news that matters to you.  Learn more

ResearchDx and CompanDX Announce Strategic Partnership

Reading time: 2 minutes

ResearchDx, LLC of Irvine, California yesterday announced a strategic partnership with CompanDX of Nottingham UK. ResearchDx and CompanDX have forged a unique partnership to offer a full capability to discover and deliver novel molecular diagnostic tests for clients in the healthcare setting. CompanDX uses its unique “Distiller” platform to deliver small composite biomarker signatures from complex data of high dimensionality, which are commonplace in clinical development of therapeutics. ResearchDx draws on its broad capability to design, produce and validate tests ready for the market and represents a new breed of service provider, the first CDO to offer turnkey solutions for companion diagnostic delivery.

“Our partnership with CompanDX completes our service offerings,” said Founders of ResearchDx, Dr. Philip Cotter and Dr Mathew Moore. “CompanDX’s unique capabilities allow us to fully integrate bioinformatics into development of a diagnostic product from early in the discovery process. Our customers can trust ResearchDx to meet scientific challenges with a focus on their business priorities.”

The new partnership will allow clients to initiate the parallel development of companion diagnostic tests from the very earliest stages of drug development. CompanDX has developed a set of industry-leading tools to deliver definitive understanding of mechanism of action and biomarkers that describe patient response. Andy Sutton, CEO of CompanDX commented, “ResearchDx occupies a space in the development of companion diagnostics that is highly complementary with our discovery platform. Both companies strive to provide innovative solutions, cutting-edge capabilities, and outcome focused delivery. We are thrilled to dovetail into ResearchDx’s downstream delivery by providing the biomarkers tailored to client’s drug candidates that will form the basis of validated tests for use in the clinic.”

Source: ResearchDx